Chinese livestock biotech companies struggle to raise capital and communicate financial plans to investors

Tianshan Biology and similar Chinese agricultural biotech firms face significant friction in equity fundraising, requiring complex regulatory documentation and investor prospectuses that are time-consuming to prepare and difficult to get approved. Companies need to clearly articulate their capital raising strategies and use of funds to specific institutional investors, but current processes involve lengthy approval cycles and unclear regulatory requirements that delay funding.